NFE2L2 and neoplasm: In addition, exogenous administration of ML-385 to inhibit the expression and function of NRF2 could suppress the radioresistance, as demonstrated by a significant decrease in tumor growth rate and experimental endpoint tumor size under radiotherapy treatment, along with marked increases in PHKG2, ferritinophagy and iron levels in NSCLC tissues, mitochondrial dysfunction and elevated expression of ferroptosis markers in tissues.